Daito Pharmaceutical ,Ltd. Receivables

The latest receivables for 4577.T is $19B as of May 2026. That compares with $20B in the prior-year period — down 6.4% year over year. Investors often review this figure alongside Daito Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4577.T's receivables moved from $20B to $19B — a 6.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Daito Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

A receivables figure of $19B for 4577.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4577.T's receivables ($19B), review year-over-year change from $20B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.